1. Introduction {#s0005}
===============

Although hallucinations and delusions represent core features of schizophrenia, a viable explanatory model that accounts for these symptoms has not been forthcoming. Recently, there has been considerable interest in the *predictive coding* (PC) framework to conceptualize the emergence and maintenance of positive symptoms ([@bb0060], [@bb0005]). PC posits that one\'s beliefs about the world (*posterior beliefs*) result from an integration of *prior beliefs* with incoming sensory information. A mismatch between what is expected (priors) and what is perceived generates a *prediction error* (PE) which then updates beliefs about future events. In the healthy brain, PEs serve to orient attention to events not accounted for by prior beliefs and motivate an update of those beliefs. In the context of psychotic symptoms, PC failures have been used to explain the formation and crystallization of delusions ([@bb0005]), as well as hallucinations ([@bb0090]). For example, inappropriate PE signaling coincident with common events may imbue those events with added salience, spurring delusion formation ([@bb0105], [@bb0075], [@bb0025]).

Despite the promising conceptual link between the PC framework and phenomenology, evidence supporting an association between experimentally-elicited PEs and symptom severity has not been consistently observed. For instance, there is considerable disagreement regarding the relationship between positive symptoms and mismatch negativity (MMN), an electrophysiological index of auditory processing that is commonly described as a prototypical PC phenomenon (e.g. [@bb0190]) and is robustly impaired in schizophrenia ([@bb0040]). The MMN is an event-related potential elicited when a sequence of regular auditory stimulation is infrequently interrupted by a tone that deviates from the standard stimulus along one or more dimensions (e.g., pitch or duration). Within the context of the PC framework, the MMN can be conceptualized as a PE that is generated when the prior belief---expectation of a standard stimulus---is violated by the presentation of a deviant tone. MMN production also appears to rely on the same biological processes that are thought to be involved in prediction formation and PE signaling. Glutamate disruption via administration of NMDA antagonists such as ketamine attenuates the MMN in humans (e.g. [@bb0185]; see also [@bb0155] for a meta-analysis) and animals ([@bb0180]). PC theory posits that prior expectations are signaled top-down most commonly via NMDA receptors and PEs most commonly via AMPA receptors. The MMN may therefore be an important biomarker that links neurochemical disruption in schizophrenia with a cognitive model that accounts for the development of psychosis.

One proposed mechanism by which this relationship emerges is through weak development of priors following NMDA disruption. Insufficient priors may yield abnormally weak PEs that manifest as MMN impairment, as well as aberrant belief formation and sensory experiences. Accordingly, reports have emerged suggesting that MMN amplitude is indeed associated with hallucinations ([@bb0050]), and positive symptoms in general ([@bb0110], [@bb0055]). However, a number of other reports failed to find a strong relationship (e.g. [@bb0015], [@bb0030], [@bb0100], [@bb0120], [@bb0150], [@bb0160]), including one study with over 800 participants in which the correlation between positive symptoms and MMN amplitude was only 0.08 ([@bb0130]). Similarly, it has been reported that MMN amplitude is associated with negative symptom severity ([@bb0020]), although this observation has also been challenged by a number of failures to replicate these findings (e.g. [@bb0010], [@bb0030], [@bb0035], [@bb0065], [@bb0095], [@bb0150]). As a result, the relationship between MMN impairment and symptom severity is not well-understood.

In the present analysis we evaluate the PC theory of psychosis by taking a meta-analytic approach to measure the relationship between MMN and symptom severity. We would interpret a significant association between MMN effect size and symptom severity as strong support for the PC model of psychosis. In the event that MMN impairment is not associated with psychosis, a secondary aim of this work was to identify sample characteristics that *are* consistently associated with reduced MMN in schizophrenia. For instance, it has been suggested that MMN impairment may be more strongly associated with low premorbid IQ than with the emergence of psychosis ([@bb0165]). This suggestion is consistent with other reports of significant associations between cognitive ability and MMN amplitude ([@bb0080], [@bb0085]); however, the results from this literature are mixed, and a meta-analytic approach is necessary to determine the robustness of this association across studies.

We examined the relationship between MMN impairment and positive and negative symptoms across 68 studies, as well as the relationship between MMN impairment and educational achievement and cognitive ability across 47 and 36 samples, respectively. We found that MMN impairment was not significantly associated with either positive or negative symptoms, but did appear to be meaningfully associated with lower educational achievement and older age in the patient group compared to healthy participants. Finally, we discuss this pattern of results and its implications for how best to consider the MMN within the PC framework.

2. Methods {#s0010}
==========

2.1. Literature search and study selection {#s0015}
------------------------------------------

The present meta-analysis is an extension of a recent meta-analysis examining MMN effect sizes by group, illness duration, and stimulus type ([@bb0040]). As such, the search parameters were identical for the present study, inclusive of all peer-reviewed research published through December 31, 2016. Briefly, the literature search was conducted through Web of Science (Thompson Reuters Corporation, New York, New York) and PubMed (National Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland) using the following search terms: schizophrenia, schizoaffective, psychosis, prodromal, bipolar disorder, mismatch negativity, and MMN (years 1987 to 2016). Although prodromal and bipolar samples were investigated in the previous study, they were not included in the present meta-analysis. Only peer-reviewed manuscripts written in English were considered. This initial search strategy identified 237 articles.

The following inclusion/exclusion criteria were then applied: (1) the MMN amplitude must be reported as a difference wave (deviant-minus-standard); (2) group differences in MMN must be reported either in terms of mean and standard deviation, *t*-test, *F-*test, effect size, or as a precise *p*-value; (3) the study must include at least one psychiatrically healthy control group and one comparison group of participants who have been diagnosed with a schizophrenia-spectrum disorder according to contemporary diagnostic standard (e.g., DSM-III or later, ICD-9 or later); (4) for consistency, only electroencephalogram (not magnetoencephalogram) studies of MMN were included in the present analysis; (5) only studies that presented original data were included; (6) only studies that reported symptom severity as a total or summary score from the PANSS or SAPS/SANS were included; and (7) only studies that reported educational achievement (in years) and/or cognitive test performance by group were included. Cognitive assessment tools such as the National Adult Reading Test ([@bb0135]), subtests from the Wechsler Adult Intelligence Scale ([@bb0195]), and subtests from the MATRICS Consensus Cognitive Battery ([@bb0145]) were among the most commonly used assessments.

Finally, there were no additional inclusion/exclusion criteria for the healthy comparison sample, with the exception that they must not have a diagnosis of schizophrenia or bipolar disorder. A list of inclusion/exclusion criteria used by individual studies can be found in Supplementary [Table 1](#t0005){ref-type="table"}.Table 1Demographic, clinical, and cognitive variables.Table 1Healthy controlsSZ-AllSZ-FSZ-CTotal N35263485419214Age32.07 (7.25)35.14 (7.31)23.40 (3.42)34.88 (6.32)Percent male57.87% (15.54%)68.46% (16.57%)62.07% (16.03%)75.96% (15.32%)Education14.56 (1.39)12.63 (0.82)11.11 (3.87)12.72 (1.20)Cognition (z-score)--− 0.89 (0.55)− 1.55 (1.98)− 1.42 (2.28)PANSS positive--16.23 (3.22)20.59 (2.70)17.19 (1.15)PANSS negative--18.61 (3.88)22.12 (3.57)18.79 (3.61)Hedges\' *g*--0.940.410.82

Using these criteria, 84 unique articles were included in the meta-analysis (Supplementary Table 2). These 84 articles included 90 samples of patients with a schizophrenia-spectrum disorder, 16 of which were first episode (SZ-F), and 9 of which were chronic samples (SZ-C). The remaining samples were comprised of patients with mixed illness duration (SZ-All). Ten of the 90 samples (4 SZ-F; 6 SZ-All) included patients with other psychotic disorders, such as Psychosis NOS and Delusional disorder (see Supplementary Table 3 for a list of diagnoses). 153 articles were rejected from the meta-analysis (see Supplementary Table 4 for the list of studies and reasons for exclusion).

2.2. Effect size and meta-regression calculations {#s0020}
-------------------------------------------------

All effect size and meta-regression calculations were conducted using Comprehensive Meta-Analysis Software (Biostat, Inc., Englewood, New Jersey). Hedges\' g ([@bb0070]) was used to estimate effect size, which is calculated as (M~1~ − M~2~)/(SD~pooled~). For all included studies, Hedges\' g was estimated on the basis of (1) group means and standard deviations; (2) *t*-tests or *F-*tests of the group effect; (3) *p*-value and sample size, or (4) Cohen\'s *d* and sample size. Many studies examined MMN amplitude across multiple deviant types, probabilities, and magnitudes; the effects of these stimulus parameters were explored in previous work ([@bb0040]). For the present analysis, only the group effect across all levels of deviant type, magnitude, and probability was examined.

To examine the relationship between effect size and symptom severity, positive and negative symptom severity scores were regressed on Hedges\' *g* in two separate meta-regressions. Symptom severity was quantified using PANSS positive and negative symptom subscales for majority of samples (*n* = 42). The SAPS and SANS was used for 20 and 26 samples, respectively; for these studies, PANSS positive and negative symptom equivalent scores were calculated using the following equations (developed by [@bb0045]):$$\mathit{PANSS\ Positive} = 11.1886 + \left( {0.2587 \ast \mathit{SAPS\ Total\ score}} \right)$$$$\mathit{PANSS\ Positive} = 9.3264 + \left( {1.1072 \ast \mathit{SAPS\ Summary\ score}} \right)$$$$\mathit{PANSS\ Negative} = 7.1196 + \left( {0.3362 \ast \mathit{SANS\ Total\ score}} \right)$$$$\mathit{PANSS\ Negative} = 6.7515 + \left( {1.0287 \ast \mathit{SANS\ Summary\ score}} \right)$$

To examine the impact of cognitive ability on MMN effect size, two meta-regressions were conducted in which (1) difference in education (in years) was regressed on Hedges\' *g*, and (2) the standardized difference in mean cognitive performance was regressed on Hedges\' *g*. Given the variety of cognitive tests employed by different research groups, we were unable to estimate ability for individual cognitive domains; rather, a coarse index of cognition was calculated by averaging the patients\' z-transformed cognitive performance across all neuropsychological tests in a given study. Given that most neuropsychological measures are substantially intercorrelated, we expect that this coarse metric provides an approximate measure of general cognitive ability. Information about educational achievement was available for 47 samples, and cognitive performance was reported for 36 samples. Of the 36 samples in which cognitive performance was measured, 13 completed a battery of neuropsychological assessments that assessed at least three cognitive domains. An additional, separate meta-regression was conducted on this subset of samples with a more thorough neuropsychological evaluation to further explore the relationship between cognitive impairment and MMN attenuation.

3. Results {#s0025}
==========

3.1. Sample characteristics and effect size by group {#s0030}
----------------------------------------------------

The combined demographic, cognitive, and clinical information from all included studies is presented in [Table 1](#t0005){ref-type="table"}. The average age for healthy, SZ-All, and SZ-C groups was 32 to 35 years, whereas the average age for SZ-F participants was 23 years. A larger percentage of participants was male in the psychosis groups (62%--76%) compared to the healthy control group (58%). On average, healthy control participants had two more years of education (14.56 years) compared to the psychosis groups (11.11--12.72 years). SZ-F participants exhibited more severe symptoms, as well as significantly reduced MMN impairment compared to the SZ-C and SZ-All groups, consistent with our previous report (*p*\'s \< 0.05) ([@bb0040]).

3.2. Symptom and cognitive variables and MMN impairment {#s0035}
-------------------------------------------------------

Of the 90 samples included in the meta-analysis, 62 included a PANSS positive or SAPS score, and 68 included a PANSS negative or SANS score. The results of the meta-regressions between positive and negative symptom severity with MMN effect size are depicted in [Fig. 1](#f0005){ref-type="fig"}a and b, respectively. There was no significant association between symptom severity and MMN effect size for positive symptoms (*B* = − 0.01, *p* = 0.51) or negative symptoms (*B* = 0.01, *p* = 0.55).Fig. 1Regression of positive symptoms on Hedges\' *g* (A) and regression of negative symptoms on Hedges\' *g* (B). Gray = SZ-All; Red = SZ-C; Blue = SZ-F. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

By contrast, there was a trend-level association between difference in education and MMN effect size (*B* = 0.11, *p* = 0.07; [Fig. 2](#f0010){ref-type="fig"}a). That is, the larger the difference in educational achievement, the larger the difference in MMN. Given that educational achievement is typically moderately correlated with cognitive ability, we would expect to see similar effects on measures of cognitive performance (36 samples). However, the relationship between cognition and effect size was not significant (*B* = − 0.01, *p* = 0.86; [Fig. 2](#f0010){ref-type="fig"}b). Similar observations were made using the subset of 13 samples that received a more thorough cognitive assessment (*B* = − 0.25, *p* = 0.61). Given the suggestive findings on educational achievement and the widely varying quality of cognitive assessment data across studies, we urge caution in accepting this null result. Additional large sample studies with adequate cognitive testing are needed to support more definitive conclusions.Fig. 2Regression of education on Hedges\' *g* (A) and regression of cognitive performance on Hedges\' *g* (B). Gray = SZ-All; Red = SZ-C; Blue = SZ-F. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

Finally, because healthy control participants were three years younger than patient samples, on average, we conducted a final meta-regression examining the relationship between age disparity and MMN impairment (86 samples). Difference in age was significantly associated with MMN effect size (*B* = − 0.04, *p* \< 0.01; [Fig. 3](#f0015){ref-type="fig"}), with larger effect sizes associated with older patient samples compared to controls.Fig. 3Regression of age disparity on Hedges\'*g*. Gray = SZ-All; Red = SZ-C; Blue = SZ-F. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 3

4. Discussion {#s0040}
=============

The primary findings of the present study call into question the simple model of PC disruption that posits a direct relationship between MMN attenuation and the severity of psychosis. We found no significant association to suggest that the magnitude of MMN impairment is correlated with positive or negative symptoms of schizophrenia. These conclusions are underscored by the observation that SZ-F individuals exhibited more severe psychopathology in both positive and negative symptom domains, and yet had significantly smaller MMN impairment compared to the SZ-All and SZ-C participants. Furthermore, previous reports indicated that individuals at high risk for developing psychosis have robustly impaired MMN---similar to that of chronic patients---but without yet having developed psychotic symptoms ([@bb0040]). These puzzling findings suggest that while MMN is severely and consistently attenuated in people with schizophrenia, this impairment is independent of the severity of clinical symptoms.

The MMN is not the only perceptual PE signal that is not robustly associated with psychosis. For example, [@bb0140] surveyed the literature and found no consistent association between weakened visual illusion susceptibility (conceptualized as a failure to develop priors) and severity of positive symptoms. In light of these findings, we suggest a modification to the current PC conceptualization that may reconcile these observations and can be tested experimentally in future studies. Put simply, the PC model of brain function and dysfunction is inherently hierarchical, yet the simple PC model of positive symptoms does not take into account this complexity. The extreme prediction of the simple model of psychosis is that failure to form predictions and generate PEs---no matter how simple or complex those predictions are---should be associated with symptom severity. In reality, however, the predictions made following a sequence of identical tones in a typical MMN paradigm are fundamentally different in precision and complexity from predictions made following a series of complex social interactions. Simple tone discrimination in the auditory cortex requires little higher order engagement and is likely to be relatively contained within early auditory processing regions. By contrast, the analysis of subtle variations in complex human behavior involves integration across time, space, and modality ([@bb0005]), and each step is translated by multiple priors and PEs. This complexity amplifies the potential for the PC machinery to fail, perhaps in a way that is more strongly associated with psychotic symptoms than are the simple inferences indexed by the MMN.

A more nuanced PC formulation therefore proposes that not all forms of prediction are directly relevant to psychosis. Rather, low-level PC abnormalities that occur during early perceptual events (e.g., MMN impairment) may reflect just one trait-like marker of psychiatric disturbance that does not appear to be necessary or sufficient for the emergence of positive symptoms. Instead, we suggest that psychotic symptoms reflect higher-order compensations for aberrant lower-order PE signals that may or may not be observed in conjunction with MMN deficits. That is, when low-level PE propagation fails (as in MMN impairment), higher-level, top-down inferences compensate ([@bb0005]). This can be observed in the case of conditioned hallucinations in psychotic patients ([@bb0125]) and in a stronger reliance on high-level priors in early psychosis and psychosis-prone individuals ([@bb0175]). To test this novel conceptualization, future work will be necessary to determine the relationship between psychosis and PEs at different hierarchical levels within the same sample of patients. Even within the scope of the MMN paradigm, it will be of interest to determine whether MMN responses to complex deviants (e.g., pattern violation) exhibits a stronger relation to symptoms than do MMN responses to simple deviants (e.g., duration violation).

Although MMN impairment is not significantly related to symptom severity, it is associated with a comparatively older patient sample. As it is known that MMN amplitude decreases with age in both patients and controls ([@bb0115]), this observation is not surprising. MMN impairment was also found to be associated with comparatively less educational achievement in the patient sample at the trend level. Though the present study found no significant association between MMN and a coarse measure of cognitive impairment, these results suggest that MMN impairment may be more closely linked with poor premorbid function, which is a significant risk factor for the development of psychosis ([@bb0170]). Such a pattern is consistent with observations that MMN is robustly impaired in individuals who are at elevated risk for developing psychosis but have not yet begun to express symptoms ([@bb0040]). Consequently, MMN impairment may serve as an important marker for identifying individuals with elevated risk for converting to psychosis.

MMN impairment, considered a key biomarker for schizophrenia, does not correlate with the severity of positive or negative symptoms. Given that MMN has been conceptualized as a PE signal, our results challenge simple PC explanations of hallucinations and delusions. They call for a deeper appreciation for the role of hierarchical representations and, taken in the context of other data, it appears that symptoms may be associated with higher levels of the hierarchy and more complex inferences than those engaged by the MMN.
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